NF-B suppresses ROS levels in BCR-ABL+ cells to prevent activation of JNK and cell death

Oncogene

Volumn 30, Issue 45, 2011, Pages 4557-4566

  Stein, S J ^a   Baldwin, A S ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

BCR ABL; IKK inhibitor; JNK; NF Kb; ROS

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOPROTEIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; ENZYME INHIBITOR; I KAPPA B KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NFKB1 PROTEIN, MOUSE;

ARTICLE; CARCINOGENESIS; CELL DEATH; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; BLOOD CELL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MOUSE; ONCOGENE; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BLOOD CELLS; CELL DEATH; CELL LINE; ENZYME ACTIVATION; ENZYME INHIBITORS; GENES, ABL; I-KAPPA B KINASE; MAP KINASE KINASE 4; MICE; NF-KAPPA B P50 SUBUNIT; REACTIVE OXYGEN SPECIES;

EID: 80755190026     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.156     Document Type: Article

References (50)

1. Basseres DS, Baldwin AS. (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830. (Pubitemid 44657854)
2. Benhar M, Engelberg D, Levitzki A. (2002). ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3: 420-425. (Pubitemid 34567428)
3. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. (2006). Targeting NF-kappaB in hematologic malignancies. Cell Death Differ 13: 748-758.
4. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M et al. (2006). Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and-independent imatinib resistance. Blood 107: 2501-2506. (Pubitemid 43345574)
5. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al. (2006). The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 20: 61-67.
6. Courtois G, Gilmore TD. (2006). Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25: 6831-6843. (Pubitemid 44657855)
7. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J et al. (2001). Induction of gadd45beta by NF-kappaB down-regulates pro-apoptotic JNK signalling. Nature 414: 308-313. (Pubitemid 33097807)
8. Dhanasekaran DN, Reddy EP. (2008). JNK signaling in apoptosis. Oncogene 27: 6245-6251.
9. Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M et al. (2007). Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21: 494-504.
10. Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, Ziegelbauer K et al. (2008). IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther 7: 391-397. (Pubitemid 351302532)
11. Felsher DW, Bishop JM. (1999). Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA 96: 3940-3944. (Pubitemid 29169015)
12. Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B et al. (1996). Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 15: 2760-2770. (Pubitemid 26176253)
13. Hamdane M, David-Cordonnier MH, D'Halluin JC. (1997). Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line. Oncogene 15: 2267-2275.
14. Hayden MS, Ghosh S. (2004). Signaling to NF-kappaB. Genes Dev 18: 2195-2224.
15. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. (2002). Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201-205. (Pubitemid 34977219)
16. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY et al. (2004). IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117: 225-237. (Pubitemid 38496242)
17. Iida T, Furuta A, Kawashima M, Nishida J, Nakabeppu Y, Iwaki T. (2001). Accumulation of 8-oxo-20-deoxyguanosine and increased expression of hMTH1 protein in brain tumors. Neuro Oncol 3: 73-81. (Pubitemid 33691764)
18. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER et al. (1997). Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652. (Pubitemid 27120541)
19. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. (2005). Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661. (Pubitemid 40343077)
20. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. (2005). Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105: 1717-1723. (Pubitemid 40223695)
21. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y et al. (2007). IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455. (Pubitemid 47198298)
22. Leppa S, Bohmann D. (1999). Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18: 6158-6162.
23. Mao X, Yu CR, Li WH, Li WX. (2008). Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 18: 879-888.
24. Mitsushita J, Lambeth JD, Kamata T. (2004). The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64: 3580-3585. (Pubitemid 38657935)
25. Naughton R, Quiney C, Turner SD, Cotter TG. (2009). Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 23: 1432-1440.
26. Pelicano H, Carney D, Huang P. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110. (Pubitemid 38736063)
27. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K et al. (2004). Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119: 529-542. (Pubitemid 39482352)
28. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. (1995). The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 92: 11746-11750. (Pubitemid 26014190)
29. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin Jr AS. (1998). A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12: 968-981. (Pubitemid 28204604)
30. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y et al. (2003). NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22: 3898-3909. (Pubitemid 36975716)
31. Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. (2000). The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275: 24273-24278. (Pubitemid 30626515)
32. Sawyers CL. (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330-1340. (Pubitemid 29196596)
33. Schimmel M, Bauer G. (2002). Proapoptotic and redox state-related signaling of reactive oxygen species generated by transformed fibroblasts. Oncogene 21: 5886-5896. (Pubitemid 35007239)
34. Senthil K, Aranganathan S, Nalini N. (2004). Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 339: 27-32. (Pubitemid 37542454)
35. Shen HM, Liu ZG. (2006). JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40: 928-939.
36. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D et al. (1999). Cell transformation by the superoxide-generating oxidase Nox1. Nature 401: 79-82.
37. Szatrowski TP, Nathan CF. (1991). Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798.
38. Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. (2002). The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 22: 8571-8579. (Pubitemid 35397172)
39. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M et al. (2001). Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313-317. (Pubitemid 33097808)
40. Toyokuni S, Okamoto K, Yodoi J, Hiai H. (1995). Persistent oxidative stress in cancer. FEBS Lett 358: 1-3.
41. Trachootham D, Alexandre J, Huang P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591.
42. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H et al. (2006). Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothio-cyanate. Cancer Cell 10: 241-252. (Pubitemid 44311067)
43. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044. (Pubitemid 34626672)
44. Ventura JJ, Cogswell P, Flavell RA, Baldwin Jr AS, Davis RJ. (2004). JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 18: 2905-2915. (Pubitemid 39602309)
45. Vogt PK. (2001). Jun, the oncoprotein. Oncogene 20: 2365-2377. (Pubitemid 32531295)
46. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M et al. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107: 8788-8793.
47. Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A. (2004). JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 13: 329-340. (Pubitemid 38229806)
48. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ et al. (2008). Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 22: 1191-1199. (Pubitemid 351833787)
49. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. (2003). Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101: 4098-4104. (Pubitemid 36857891)
50. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T et al. (2005). A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145: 178-192. (Pubitemid 40756522)